Sugi Predict

Sugi Predict / Compounds / SCHEMBL3672494

SCHEMBL3672494

SCHEMBL3672494

Ic1cn(Cc2ccccc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 1/20 0.51
▸ CYP3A4 P08684 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ CYP2E1 P05181 1/20 0.50
▸ CYP2A6 P11509 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2B6 P20813 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ CYP11B1 P15538 3/20 0.47
▸ CYP11B2 P19099 3/20 0.47
▸ CYP19A1 P11511 3/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TBXAS1 P24557 1/20 0.47
▸ QPCT Q16769 1/20 0.47
▸ CYP4Z1 Q86W10 1/20 0.47
▸ QPCTL Q9NXS2 1/20 0.47
▸ KDM4C Q9H3R0 2/20 0.47
▸ KDM5A P29375 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7265268 0.79 TSHR (0.45) HPGDSCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL19925217 0.78 HPGDS (0.53) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL9598245 0.78 CYP3A4 (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL28417071 0.78 HPGDS (0.49) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL15707234 0.78 CDK5 (0.50) CYP11B1CYP19A1MAPTKDM4CKDM5B
SCHEMBL25395574 0.77 HPGDS (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL2972635 0.77 HPGDS (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL19936854 0.77 HPGDS (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL1196872 0.77 HPGDS (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6
SCHEMBL6502452 0.77 HPGDS (0.51) HPGDSCYP3A4CYP2D6CYP2E1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 — — CN disclosed
CN-114466839-B TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-01-07 — — CN disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
CN-111936496-B Heterocyclic compounds useful as medicaments 马萨里克大学 2023-12-29 — — CN disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11498920-B2 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors MASARYKOVA UNIVERZITA (CZ) 2022-11-15 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
US-8853203-B2 Diazepinone derivatives NOVARTIS AG (CH) 2014-10-07 — — US disclosed
US-8853203-B2 Diazepinone derivatives NOVARTIS AG (CH) 2014-10-07 — — US disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 — — US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 — — CN disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 — — EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 — — US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885
US-11498920-B2 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors MALT1, BCL3, MCL1 HPGDS 319/4885CYP3A4 1521/4885CYP2D6 3573/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 HPGDS 2598/4885CYP3A4 785/4885CYP2D6 1318/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885
US-20140057902-A1 Diazepinone derivatives ADRB1, ADRB2, BRD4 HPGDS 1252/4885CYP3A4 261/4885CYP2D6 65/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 HPGDS 1573/4885CYP3A4 1648/4885CYP2D6 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.